Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

307.86
Delayed Data
As of 4:00pm ET
 +1.73 / +0.57%
Today’s Change
223.02
Today|||52-Week Range
333.65
+0.49%
Year-to-Date
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug 24 / Zacks.com - Paid Partner Content
Ionis Pharmaceuticals Inc Begins to Shift Focus
Aug 16 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Aug 17 / Zacks.com - Paid Partner Content
Biogen and Ionis Pharmaceuticals climb on upbeat drug trials
Aug 01 / FT.com - Paid Partner Content
Better Buy: Amgen Inc. vs. Biogen
Aug 17 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close306.13
Today’s open305.24
Day’s range305.00 - 309.00
Volume1,065,392
Average volume (3 months)1,886,148
Market cap$67.1B
Dividend yield--
Data as of 4:00pm ET, 08/30/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+16.23%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)-3.87%
P/E ratio18.0
Price/Sales7.60
Price/Book7.14

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.25-0.32%
ILMNIllumina Inc-1.43-0.84%
AMGNAmgen-0.75-0.44%
NBIXNeurocrine Bioscienc...-0.14-0.28%
Data as of 4:00pm ET, 08/30/2016

Financials

Next reporting dateOctober 19, 2016
EPS forecast (this quarter)$5.00
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Search for Jobs